Related Experiment Video
Updated: Sep 20, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Soluble TREM2 is associated with death and cardiovascular events after acute ischemic stroke: an observational study
Yaling Lu1, Yu Zhao2, Qi Zhang1
1Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu, China.
Background:
Soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. We aimed to prospectively investigate the associations between plasma sTREM2 and clinical outcomes in acute ischemic stroke (AIS) patients.
Methods:
Study participants were from the China Antihypertensive Trial in Acute Ischemic Stroke, plasma sTREM2 levels in the acute phase of AIS were measured in 3285 participants. The study outcomes were death, cardiovascular events and severe disability at 1 year after AIS. Cox proportional hazards models or logistic regression models were performed to examine the associations of plasma sTREM2 and clinical outcomes.
Results:
After 1-year follow-up, 288 participants (8.8%) experienced cardiovascular events or died. Multivariable-adjusted hazard ratios or odds ratios (95% confidence intervals) for the highest quartile of sTREM2 were 1.57 (1.11-2.21) for the composite outcome of death and cardiovascular events, 1.68 (1.09-2.60) for death, and 1.53 (1.08-2.18) for death or severe disability compared to the lowest quartile. Moreover, incorporation sTREM2 into traditional risk factors model significantly improved risk prediction of the composite outcome of death and cardiovascular events as evidenced by net reclassification index and integrated discrimination improvement (all p values < 0.05). There were joint effects of sTREM2 and galectin-3 on death and cardiovascular events. Participants with simultaneous elevation of sTREM2 and galectin-3 levels had the highest risk of the composite outcome of death and cardiovascular events.
Conclusions:
Elevated sTREM2 levels were independently associated with increased risks of death and cardiovascular events after AIS.
Insights
Elevated soluble triggering receptor expressed on myeloid cells 2 (sTREM2) levels in acute ischemic stroke (AIS) patients are linked to higher risks of death and cardiovascular events. This biomarker may improve risk prediction after stroke.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Medicine
Background:
- Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) reflects microglia activation and is associated with neuroinflammation and neuronal injury.
- Investigating plasma sTREM2 in acute ischemic stroke (AIS) patients is crucial for understanding post-stroke outcomes.
Purpose of the Study:
- To prospectively examine the association between plasma sTREM2 levels and clinical outcomes in AIS patients.
- To determine if sTREM2 improves risk prediction for adverse events following AIS.
Main Methods:
- Plasma sTREM2 levels were measured in 3285 AIS patients from the China Antihypertensive Trial in Acute Ischemic Stroke.
- Cox proportional hazards and logistic regression models assessed associations between sTREM2 and outcomes (death, cardiovascular events, severe disability) at 1-year follow-up.
Main Results:
- Higher sTREM2 levels were associated with increased risks of death (HR 1.68; 95% CI 1.09-2.60) and a composite of death or cardiovascular events (HR 1.57; 95% CI 1.11-2.21).
- sTREM2 incorporation improved risk prediction models for composite outcomes.
- Joint elevation of sTREM2 and galectin-3 indicated the highest risk for death and cardiovascular events.
Conclusions:
- Elevated plasma sTREM2 is an independent predictor of increased mortality and cardiovascular events after AIS.
- sTREM2 may serve as a valuable biomarker for risk stratification in AIS patients.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

